AP1M2 and prostate carcinoma: AP1M2 expression differences were revealed simultaneously among various cancers and normal control, which indicated that AP1M2 was highly expressed and significant in breast cancer, liver cancer, lung cancer, bile duct cancer, prostate cancer, gastric cancer, thyroid cancer, and common genital tumors compared to normal tissues.